#United States #Philadelphia #Children's Hospital #B-ALL

Significant Advancement in Pediatric Cancer Treatment

Recent research from the Children’s Hospital of Philadelphia (CHOP) in collaboration with the Children’s Oncology Group (COG) has resulted in a pivotal Phase 3 study, indicating that the integration of blinatumomab—an innovative bi-specific T-cell engager—into chemotherapy drastically enhances survival rates for newly diagnosed pediatric patients with B-cell acute lymphoblastic leukemia (B-ALL).

Published in the esteemed New England Journal of Medicine, these findings are set to be unveiled at the upcoming 66th American Society of Hematology Annual Meeting in San Diego on December 8.

Background on the Study

Blinatumomab has changed the landscape of leukemia treatment since its approval for children and adults dealing with relapsed B-ALL a decade ago. However, with relapse remaining a significant challenge, especially in children suffering from standard-risk (SR) B-ALL—nearly half of which involve recurrences—researchers were determined to investigate its effectiveness from the moment of diagnosis.

Dr. Stephen P. Hunger, co-author of the study, emphasized the team’s commitment to enhancing cure rates while minimizing side effects for young cancer patients. The study tested whether adding blinatumomab, administered in two separate 28-day cycles, could improve disease-free survival rates in children diagnosed with SR B-ALL between June 2019 and June 2024.

Study Results

The Phase 3 trial, known as AALL173, involved a total of 1,440 pediatric patients, with an average age of four. Out of these, 835 were classified as SR average (SR-Avg) and 605 as SR high (SR-High). An impressive 96.0% of patients receiving chemotherapy alongside blinatumomab achieved a three-year disease-free survival rate (DFS), in contrast to only 87.9% among those who only received chemotherapy. Among SR-Avg patients specifically, the DFS soared to 97.5% with the inclusion of blinatumomab.

Dr. David T. Teachey, another co-author of the study, described these findings as a major clinical leap forward, asserting that the combination of blinatumomab and chemotherapy is now considered the safest and most effective treatment for children suffering from B-ALL.

Future Directions

Looking ahead, researchers are optimistic about extending the study's findings to higher-risk pediatric patients and improving access to this vital treatment for children and their families globally. The research received backing from the National Institutes of Health and the St. Baldrick's Foundation, underscoring its significance in pediatric oncology.

About Children's Hospital of Philadelphia (CHOP)

Founded in 1855, CHOP is recognized as the nation’s first pediatric hospital, boasting a long tradition of exemplary patient care, comprehensive training for future healthcare professionals, and groundbreaking research initiatives. With its vast network and resources, CHOP continues to be a leader in advancing pediatric health and providing innovative treatments that positively impact children worldwide.

For more information on the latest findings and CHOP’s extensive pediatric care services, please visit chop.edu.